Compazine Shortage: What Providers and Prescribers Need to Know in 2026

Prochlorperazine (Compazine) has been a first-line antiemetic and antipsychotic for decades, but supply chain disruptions that began well before 2020 have intensified, creating significant challenges for prescribers in outpatient, inpatient, and emergency settings. This article is written for prescribers, pharmacists, and clinical teams who need practical, evidence-based guidance on managing prochlorperazine availability in 2026.

Current Shortage Status as of 2026

As of early 2026, the following prochlorperazine formulations are affected:

Prochlorperazine edisylate injection (5 mg/mL): Listed on the ASHP Drug Shortage Database with recurring availability gaps dating back to 2015. Multiple manufacturers have experienced production disruptions. This has the greatest impact on ED antiemetic protocols and IV/IM migraine management.

Oral tablets (5 mg, 10 mg): Intermittent retail pharmacy shortages. Chain pharmacies are most affected; independent pharmacies may have better access.

Rectal suppositories (25 mg): Intermittently unavailable but sometimes accessible when tablets are not, due to separate manufacturers.

Why Is This Shortage So Persistent?

Understanding the root causes helps set realistic expectations for resolution:

Economic disincentives: Prochlorperazine tablets sell for approximately $0.30 to $1.00 per unit at wholesale, leaving minimal margin to incentivize production expansion or new market entrants.

Sterile manufacturing constraints: Injectable production requires specialized facilities with high regulatory compliance burden. FDA remediation timelines following inspections are extended.

Concentrated manufacturer base: A single manufacturer stoppage can cause national supply disruption when so few companies produce a drug.

API sourcing: Active pharmaceutical ingredient supply from international sources introduces geopolitical and logistical vulnerability.

Clinical Impact by Setting

The shortage has differential impacts depending on clinical context:

Emergency Medicine: Prochlorperazine IV/IM is a first-line agent for ED antiemetic protocols and acute migraine management. Injectable shortages directly affect these protocols and require institutional alternatives.

Oncology: While 5-HT3 antagonists are the standard of care for chemotherapy-induced nausea, prochlorperazine is used as adjunct or rescue antiemetic therapy. Oral shortages can disrupt outpatient CINV management.

Neurology: Oral prochlorperazine is used for outpatient migraine and vestibular disorder management. Tablet shortages affect patients who rely on it for chronic migraine or vertigo.

Psychiatry: Although not a first-line antipsychotic by current standards, some patients with stable schizophrenia are maintained on prochlorperazine. Shortage creates need for careful transition planning.

Recommended Therapeutic Alternatives by Indication

Severe nausea/vomiting (outpatient, oral): Ondansetron 4-8 mg PO q8h; promethazine 12.5-25 mg PO q4-6h; metoclopramide 10 mg PO TID (short-term only, boxed warning for tardive dyskinesia with use beyond 12 weeks)

ED acute migraine (IV/IM): Metoclopramide 10 mg IV/IM; ketorolac 15-30 mg IV/IM; haloperidol 2.5 mg IV (evidence supports use for migraine)

CINV (adjunct/rescue): Olanzapine 5-10 mg PO; dexamethasone; lorazepam as adjunct therapy

Formulation switching: If oral tablets are unavailable, consider prochlorperazine rectal suppositories (25 mg BID) from a different manufacturer. Confirm availability with your pharmacy before writing the prescription.

Patient Communication During the Shortage

Proactive patient communication reduces unnecessary burden on your practice. When prescribing prochlorperazine or managing existing patients, consider this approach:

Acknowledge the shortage at the time of prescribing — this prevents frustrated calls and follow-up visits when the pharmacy cannot fill the script.

Provide a written alternative prescription simultaneously — name your preferred substitute and dose so patients do not need a second visit.

Direct patients to medfinder.com/providers — a tool that identifies retail pharmacies with current prochlorperazine stock, saving patients hours of phone calls.

Schedule appropriate follow-up to assess response if a patient is switched to an alternative medication.

Shortage Monitoring Resources for Providers

ASHP Drug Shortage Database (ashp.org) — updated formulation-level shortage status

FDA Drug Shortages Database (fda.gov) — official FDA shortage declarations

medfinder for Providers (medfinder.com/providers) — real-time retail pharmacy stock data for patient outpatient prescriptions